About Faeth

3 teams, 3 discoveries, one paradigm shift

Faeth was born from three leading research teams with three separate discoveries coming together around one big idea: We can use metabolism to beat cancer.

The science of cancer meets the power of metabolism

Cancer therapies have remained largely unchanged for decades. At Faeth, we believe that the use of metabolism and precision nutrition will join surgery, radiotherapy, small molecules, and biologics as a foundational treatment for cancer.

Faeth is a data-driven, evidence-based company with a deep mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. Our discovery platform matches tumor genotypes with treatment regimens combining therapeutic targets and precision diets to improve patient outcomes. We are in clinical trials now.

Our team of world-leading scientists and founders

Faeth leadership team

ec0f98_52b58147da104e948680b0dc89d9d8e8_mv2

Anand Parikh, JD

CEO & Co-Founder

Former CFO at Virta Health

Oliver Maddocks, PhD

Chief Scientific Officer & Co-Founder

Former Professor of Cancer Biology & Metabolism, University of Glasgow

Debbie Chirnomas, MD, MPH

Chief Medical Officer

Leader in clinical development, formerly at Arvinas, Gamida Cell, Pfizer

Ryan Whitney

Head of Food Operations

Previously Chief of Staff at Faeth, Strategic Finance Lead at Virta Health

Gini Casadas

Head of Clinical Operations

Previously led clinical trials at Novartis, Audentis, and Vir Biotechnology

Rami Jassim, MD

Head of Clinical Development

Formerly led US Immuno-Oncology at AstraZeneca as the Senior Medical Director

Bridie Gahan

Head of Strategy & Finance

Previously Chief of Staff at Faeth,Former venture capital investor

Burnett King

Head of Product

Previously product leader at Amazon, Expedia

Faeth founders

Anand Parikh, JD

CEO & Co-Founder

Former CFO at Virta Health

Oliver Maddocks, PhD

Chief Scientific Officer & Co-Founder

Former Professor of Cancer Biology & Metabolism, University of Glasgow

Lew Cantley, PhD

Dana Farber Cancer Institute, Harvard. Founder: Agios (NASDAQ), Petra, Volastra

Greg Hannon, PhD

Director of CRUK Cambridge Institute

Scott Lowe, PhD

Chair of Cancer Biology & Genetics at Memorial Sloan Kettering, Founder: ORIC (NASDAQ)

Sid Mukherjee, MD PhD

Asst. Prof., Columbia, Pulitzer Prize Winner, Time 100 Most Influential People, Founder: Vor (NASDAQ)

Karen Vousden, PhD

Chief Scientist of CRUK, Group Leader, Crick Institute, Director, Bristol Myers Squibb

Marcus Goncalves, MD PhD

Asst. Prof., Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine New York

Ben Hopkins, PhD

Asst. Prof., Genetics Genomics & Oncological Sciences, Icahn School of Medicine at Mount Sinai New York

Simon Knott, PhD

Asst. Prof., Biomedical Sciences & Associate Director, Center for Bioinformatics and Functional Genomics, Cedars Sinai Medical Center Los Angeles

Faeth Scientific Advisory Board

John Blenis

Pharmacologist, Weill Cornell

Heather Christofk, PhD

Associate Director of Basic and Translational Research, UCLA Johnson Comprehensive Cancer Center; Professor of Biological Chemistry, David Geffen School of Medicine at UCLA; Co-Director, UCLA Metabolomics Center

Ralph DeBerardinis, MD PhD

Investigator, Howard Hughes Medical Institute; Chief of the Division of Genetics and Metabolism in the Department of Pediatrics, UT Southwestern Medical Center